DRNA - Dicerna shares slide 30% despite pivotal nedosiran study hitting primary endpoint

Dicerna Pharmaceuticals (NASDAQ:DRNA) shares have slid more than 30% post-market despite meeting the primary endpoint in a pivotaql  trial of nedosiran in patients with primary hyperoxaluria (PH). The likely reason for the decline is that urinary oxalate ((Uox)) excretion reductions were significant in participants with PH1, a subtype of the disease, while patients with PH2, another subtype, showed "inconsistent" results in this trial, the company said. In the trial, nedosiran achieved the primary endpoint, demonstrating a "statistically significant" reduction from baseline in ("Uox") compared to placebo (p<0.0001). The study also achieved the key secondary endpoint, with a significantly higher proportion of patients given nedosiran achieving and sustaining normal or near-normal Uox at two or more consecutive visits after day 90 compared to placebo (p=0.0025). Nedosiran was generally well tolerated in the study with an overall adverse event profile consistent with previously reported data from PHYOX trials. The company expects to submit an NDA to

For further details see:

Dicerna shares slide 30% despite pivotal nedosiran study hitting primary endpoint